One of the major mechanisms underlying trastuzumab resistance in breast cancer is the dysregulation of HER2 downstream signaling substrate, including the phosphatidylinositol 3-kinase/protein kinase B (PI3K/AKT) pathway [16, 17]. Here, AKT1 is linked to breast cancer.